Janssen's canagliflozin clears Januvia and glimepiride at Phase III hurdle
This article was originally published in Scrip
Executive Summary
Data from the first two head-to-head pivotal trials of Janssen/Mitsubishi Tanabe Pharma 's SGLT2 inhibitor show that it has improved efficacy over established antidiabetics, without any sign yet of the cancer and liver signals that have delayed the lead product in this class, AstraZeneca/ Bristol-Myers Squibb 's dapagliflozin, in the US.